15 assets in Neurofibromatosis Type 1

Therapeutic assets addressing Neurofibromatosis Type 1, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Trametinib Neurofibromatosis Type 1	Novartis Pharmaceuticals	P4	B (61)
Dabrafenib Neurofibromatosis Type 1	Novartis Pharmaceuticals	P4	B (60)
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Neurofibromatosis Type 1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Neurofibromatosis Type 1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Busulfanum Neurofibromatosis Type 1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cyclophosphamide Neurofibromatosis Type 1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Fludarabine Neurofibromatosis Type 1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Melphalan Neurofibromatosis Type 1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Rituximab Neurofibromatosis Type 1	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Mirdametinib Neurofibromatosis Type 1	University of Alabama at Birmingham	P2	CCC (50)
Abm-168 Neurofibromatosis Type 1	ABM Therapeutics Corporation	P1	CC (43)
Avutometinib Neurofibromatosis Type 1	Memorial Sloan Kettering Cancer Center	P1	CC (43)
Dcc-3084 Neurofibromatosis Type 1	Deciphera Pharmaceuticals, LLC	P1	CC (43)
Pas-004 Capsules Neurofibromatosis Type 1	Pasithea Therapeutics Corp.	P1	CC (43)
Pas-004 Tablets Neurofibromatosis Type 1	Pasithea Therapeutics Corp.	P1	CC (43)